Showing 4641-4650 of 5957 results for "".
- Alcon Inaugurates Company’s Largest European Eye Health Education and Training Center in Barcelonahttps://modernod.com/news/alcon-inaugurates-companys-largest-european-eye-health-education-and-training-centre-in-barcelona/2480404/Alcon officially opened the new Alcon Experience Center (AEC) in Barcelona, one of Europe's largest eye health education and training facilities, offering eye care professionals the opportunity to learn and gain hands-on experience with the latest innovations in ophthalmology and optometry. T
- Prism Vision Group Acquires Three New Practiceshttps://modernod.com/news/prism-vision-group-acquires-three-new-practices/2480398/PRISM Vision Group announced that it has recently acquired Bethlehem Eye Associates in Bethlehem, Pennsylvania; Schefkind Eye Care with two locations in Alexandria, Virginia; and Carabin Eye Care in New Milford, New Jersey. Terms of the deals were not disclosed.
- CooperVision Presents Presbyopia Research, Introduces MyDay Daily Disposable Multifocal at Academy 2021https://modernod.com/news/coopervision-presents-presbyopia-research-introduces-myday-daily-disposable-multifocal-at-academy-2021/2480390/As part of the American Academy of Optometry 2021 virtual press conference, CooperVision presented results of research into the daily complexity of dealing with presbyopia and how this may affect clinical choices. The work was conducted in support of the launch of CooperVision’s new MyDay&n
- EyeCare Partners Acquires CEI Vision Partnershttps://modernod.com/news/eyecare-partners-acquires-cei-vision-partners/2480383/EyeCare Partners (ECP) announced it entered into an agreement to acquire CEI Vision Partners (CVP), a network of ophthalmology practices in the Midwest and Mid-Atlantic. Financial terms of the transaction were not disclosed. The deal will create a combined group of more t
- EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeuticshttps://modernod.com/news/eyegate-pharmaceuticals-closes-acquisition-of-bayon-therapeutics/2480376/EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’
- Ocular Therapeutix's Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Does Not Meet Primary Endpointhttps://modernod.com/news/ocular-therapeutixs-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease-does-not-meet-primary-endpoint/2480372/Topline results from Ocular Therapeutix's phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED) did not meet its primary endpoint of increased tear production at 12 weeks. The phase 2, US-based, randomized, double-masked,
- Aurion Biotech Names Members of Medical Advisory Boardhttps://modernod.com/news/aurion-biotech-names-members-of-medical-advisory-board/2480358/Aurion Biotech announced the company’s medical advisory board, composed of the world’s most eminent ophthalmologists. The board will collaborate with the company’s executive team in clinical development, and is chaired by Edward Holland, MD, who was recently
- Stephen D. McLeod, MD, Selected as Next CEO of American Academy of Ophthalmologyhttps://modernod.com/news/stephen-d-mcleod-md-selected-as-next-ceo-of-american-academy-of-ophthalmology/2480346/The American Academy of Ophthalmology board of trustees announced the unanimous selection of Stephen D. McLeod, MD, 57, as the Academy’s next chief executive officer (CEO). Dr. McLeod currently is the Theresa M. and Wayne M. Caygill, M.D. Distinguished Professor and Chair, Department of Oph
- SyncThink Receives Second FDA Clearance for Mobile, Rapid Test for Concussionhttps://modernod.com/news/syncthink-receives-second-fda-clearance-for-first-mobile-rapid-test-for-concussion/2480327/SyncThink has received FDA clearance for its EYE-SYNC technology as an aid to concussion, or mild traumatic brain injury (mTBI) diagnosis. EYE-SYNC received breakthrough device designation from the FDA in 2019, following the initial clearance and commercialization of the technology plat
- Nidek Launches Retina Scan Duo 2 OCT/Fundus Camerahttps://modernod.com/news/nidek-launches-retina-scan-duotm-2-octfundus-camera/2480323/Nidek has announced the launch of the Retina Scan Duo 2, a combined OCT and fundus camera system. The Retina Scan Duo 2 incorporates new features designed to enhance screening and clinical efficiency, in addition to user-friendly features that were incorporated from the previous model.<